Santhera Pharmaceuticals (Switzerland) Ltd.

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases.
In September 2015 our product, Raxone®, received European Marketing Authorization in the treatment of patients with LHON (Leber's Hereditary Optic Neuropathy). Raxone® is not only the first and only medicine approved for this condition, but it is also the first medicine approved for any mitochondrial disorder.
Raxone® is also investigated for the treatment of Duchenne Muscular Dystrophy (DMD) and Primary Progressive Multiple Sclerosis (PPMS). In addition, Santhera’s pipeline includes omigapil, an investigational drug with anti-apoptotic properties, a compound in development to address unmet medical needs for patients with Congenital Muscular Dystrophy (CMD).
In February 2018, Santhera obtained the worldwide, exclusive rights to develop and commercialize POL6014, an innovative macrocycle elastase inhibitor with the potential to treat Cystic Fibrosis and other Pulmonary Diseases.

For more information, please visit the company's website www.santhera.com

Offres d'emploi

Mitarbeiter/in Empfang und Rezeption (100%)

Santhera Pharmaceuticals (Switzerland) Ltd.Pratteln

19.07.2018

Evaluations

Actuellement aucun évaluation
Aidez les autres candidats et soyez le premier à évaluer cette entreprise.

Emplacement

Santhera Pharmaceuticals (Switzerland) Ltd.

Hohenrainstrasse
4133 Pratteln

http://www.santhera.com

Ce site web utilise des cookies afin d'offrir le meilleur service possible. Pour plus d’informations, consultez nos Conditions générales et nos informations sur la protection des données.